Between 1985 and 1993, research on immunotherapy with interleukin-2 (IL-2), a cytokine that promotes T cell growth, greatly progressed, with its approval by the Food and Drug Administration (FDA), in 1998, as the first immunotherapy for advanced melanoma [32,39]. This evidence concerns the gene IL2 and melanoma.